Physician profile
Rebekka L Amick
NPI 1598126427
$5,985.88
in general payments reported to CMS, 2019-2025
34 companies · $1,293 in 2025
The $1,293 reported for 2025 was more than what 90% of Gerontology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $161).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $950 · 2022: $1,480 · 2023: $1,301 · 2024: $962 · 2025: $1,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,555.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,399.47 | 2021-2025 | Wegovy |
| Abbvie INC. | $321.29 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $302.13 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $281.94 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $266.23 | 2023-2025 | Ultomiris |
| Axsome Therapeutics, INC. | $228.67 | 2023-2024 | Auvelity |
| Grifols USA, LLC | $199.06 | 2022-2023 | Prolastin-C Liquid |
| Amgen INC. | $197.59 | 2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.46 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $166.38 | 2022 | |
| Scynexis, INC. | $140.16 | 2022 | |
| Janssen Pharmaceuticals, INC | $137.19 | 2021 | |
| Bioventus LLC | $136.39 | 2022 | |
| Eisai INC. | $124.29 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $124.09 | 2025 | Austedo Xr |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $123.82 | 2025 | Fanapt |
| Horizon Therapeutics Plc | $123.42 | 2021 | |
| Medtronic, INC. | $117.66 | 2023 | Signia |
| Neurelis, INC. | $114.52 | 2025 | Valtoco |
| Idorsia Pharmaceuticals US INC | $112.90 | 2023 | Quviviq |
| Insmed, INC. | $111.90 | 2025 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $111.03 | 2022 | |
| Janssen Scientific Affairs, LLC | $106.61 | 2023 | Xarelto |
| Melinta Therapeutics, LLC | $103.94 | 2024 | Rezzayo |
| Alnylam Pharmaceuticals INC. | $101.39 | 2022 | |
| Avanir Pharmaceuticals, INC. | $100.44 | 2021 | |
| Alkermes, INC. | $94.97 | 2022 | |
| Lilly USA, LLC | $89.28 | 2025 | Zepbound |
| Csl Behring | $88.24 | 2021 | |
| Dexcom, INC. | $78.89 | 2023 | Dexcom G6 Transmitter |
| Harmony Biosciences LLC | $63.45 | 2024 | |
| Grt US Holding, INC. | $57.73 | 2022 | |
| Boston Scientific Corporation | $52.35 | 2022 | |
| Neurocrine Biosciences, INC. | $34.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebekka Amick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.